Physician profile
James Comazzi
NPI 1144268392
$733.21
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $332 · 2020: $113 · 2021: $289.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $250.71 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.03 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $83.78 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $53.10 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $52.15 | 2019 | |
| Pfizer INC. | $42.49 | 2019-2021 | |
| Boston Scientific Corporation | $35.07 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.13 | 2019 | |
| Amgen INC. | $31.38 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $20.51 | 2019 | |
| Medtronic, INC. | $17.86 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Comazzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.